Valuation: Applied Therapeutics, Inc.

Market Cap 15.25M 13.28M 12.57M 11.42M 21.33M 1.46B 21.44M 150M 57.88M 742M 57.27M 56M 2.38B P/E 2023
-2.36x
P/E 2024 -1.13x
Enterprise Value -61.36M -53.44M -50.58M -45.95M -85.85M -5.88B -86.27M -602M -233M -2.99B -230M -225M -9.56B EV / Sales 2023
20,974,366x
EV / Sales 2024 50,596,512x
Free-Float
95.24%
Yield 2023 *
-
Yield 2024 -
1 day+0.19%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
19.14
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 03/02/2026
Corporate Secretary - 03/02/2026
Corporate Officer/Principal - 21/01/2025
Director TitleAgeSince
Director/Board Member - 03/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
2/3/26 A Issuer sale

Director

328,690 0.2278%
2/3/26 A Issuer sale

Director

393,053 0.2724%
2/3/26 A Issuer sale

Director

328,690 0.2278%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%-74.96%-94.46% 15.7M
+1.76%+3.88%+46.85%+101.12% 70.89B
+0.30%+1.78%+40.52%+78.00% 62.32B
+1.14%-2.59%-14.37%+365.92% 27.07B
+2.95%+2.34%+0.52%-12.74% 24.78B
+0.31%+7.73%+26.85%-15.89% 20.59B
-0.83%-9.47%+174.16%+295.44% 15.52B
+3.01%+1.85%+44.63%+168.18% 14.49B
+2.43%+4.24%-2.05%+847.59% 14.14B
+1.00%+0.24%+28.02%+203.83% 12.35B
Average +1.22%+1.47%+27.02%+193.70% 26.22B
Weighted average by Cap. +1.23%+2.50%+36.96%+163.30%

Financials

2023 2024
Net sales 9.99 8.7 8.24 7.48 13.98 957.04 14.05 98.12 37.94 486.38 37.54 36.7 1.56K 0.46 0.4 0.38 0.34 0.64 43.58 0.64 4.47 1.73 22.15 1.71 1.67 70.89
Net income -120M -104M -98.73M -89.7M -168M -11.47B -168M -1.18B -455M -5.83B -450M -440M -18.66B -106M -92M -87.07M -79.11M -148M -10.12B -149M -1.04B -401M -5.14B -397M -388M -16.46B
Net Debt -49.12M -42.78M -40.49M -36.79M -68.73M -4.7B -69.07M -482M -186M -2.39B -185M -180M -7.65B -76.6M -66.72M -63.15M -57.37M -107M -7.34B -108M -752M -291M -3.73B -288M -281M -11.94B
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. APLT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!